High Frequency of Rifampin Resistance Identified in an EpidemicClostridium difficileClone from a Large Teaching Hospital
Open Access
- 15 February 2009
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 48 (4) , 425-429
- https://doi.org/10.1086/596315
Abstract
Background. Rifampin is used as adjunctive therapy for Clostridium difficile–associated disease, and the drug's derivative, rifaximin, has emerged asKeywords
This publication has 16 references indexed in Scilit:
- Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficileAntimicrobial Agents and Chemotherapy, 2008
- Multilocus Variable-Number Tandem-Repeat Analysis for Investigation of Clostridium difficile Transmission in HospitalsJournal of Clinical Microbiology, 2006
- The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genomeNature Genetics, 2006
- A Predominantly Clonal Multi-Institutional Outbreak ofClostridium difficile–Associated Diarrhea with High Morbidity and MortalityNew England Journal of Medicine, 2005
- An Epidemic, Toxin Gene–Variant Strain ofClostridium difficileNew England Journal of Medicine, 2005
- Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in QuebecCMAJ : Canadian Medical Association Journal, 2005
- A Large Outbreak ofClostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone UseInfection Control & Hospital Epidemiology, 2005
- Novel rpoB Mutations Conferring Rifampin Resistance on Bacillus subtilis : Global Effects on Growth, Competence, Sporulation, and GerminationJournal of Bacteriology, 2004
- Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and ComplicationsAnnals of Surgery, 2002
- In vitro Activity of Rifaximin, Metronidazole and Vancomycin against Clostridium difficile and the Rate of Selection of Spontaneously Resistant Mutants against Representative Anaerobic and Aerobic Bacteria, Including Ammonia-Producing SpeciesChemotherapy, 2000